Cardiva Medical, Inc. designs and develops vascular access management products that facilitate rapid hemostasis following diagnostic and interventional endovascular procedures. Since its founding, Cardiva has introduced a series of advanced vascular access management technologies designed to help the body heal itself.
Cardiva Medical, Inc. is a privately-held company funded by leading venture capital investors, including PTV Healthcare Captial, Canepa Advanced Healthcare Fund, L.P and Amkey Ventures LLC. Cardiva was presented the prestigious Frost & Sullivan Entrepreneurial Company Award, which recognizes entrepreneurial excellence in the U.S. angioplasty and vascular closure device markets.
Cardiva's CATALYST Manual Compression Assist Device and its predecessors have been utilized effectively in over 400,000 procedures since the product launched in 2005. CATALYST II and CATALYST III, specifically designed for heparinized patients, have both gained wide acceptance by physicians and hospitals. Our latest advancement is the VASCADE® Vascular Closure System, the only extravascular device to offer collagen and a dual mechanism of action; physiological and mechanical.
It is a fully integrated, completely bioabsorbable, easy to use vascular closure system that demonstrated safety and efficacy in
a wide range of patients.